1025MO First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.